Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Peripheral blood B-cell early regeneration predicts clinical relapse and guides preemptive therapy after CAR-T treatment in acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYingwei LiFAFurun An

Discussion

Loading...

Member takes

Overview

Survival analysis shows early B-cell regeneration predicts relapse in acute lymphoblastic leukemia patients, indicating timely chemotherapy improves outcomes.

Key Points

  • To evaluate the relationship between early B-cell regeneration and clinical relapse in R/R B-ALL patients after CAR-T treatment.
  • Retrospective analysis of clinical data from 55 R/R B-ALL patients who received CD19 CAR-T treatment.
  • Analysis of peripheral blood B-cell count, bone marrow MRD, and CAR gene copy number.
  • Comparison of relapse-free survival rates between different preemptive therapies.
  • CR rate was 81.8% post-CD19 CAR-T treatment.
  • Median relapse-free survival was 290 days; median overall survival was 870 days.
  • Clinical relapse correlated with early peripheral blood B-cell regeneration within 45 days of CAR-T infusion.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d210https://doi.org/10.1182/blood-2025-6882
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up2024 · 13 citations
  2. 2Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance2025 · 3 citations
  3. 3Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study2025
  4. 4Identification of independent prognostic factors in relapsed pediatric B-ALL patients receiving CD19 CAR-T without consolidative HSCT.2026
  5. 5Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis2025